On February 16, 2010, a Risk Evaluation and Mitigation Strategies (REMS) program to ensure safe use of erythropoiesis-stimulating agents (ESAs) was approved by the US Food and Drug Administration (FDA).
More than 2.5 million breast cancer survivors live in the US today. This number will continue to grow thanks to early detection and advances in treatment that are making early stage breast cancer an increasingly curable disease.
With about 12 million cancer survivors living in the US, cancer affects millions of working Americans. Improvements in early detection and treatment have resulted in a significant number of newly diagnosed and long-term survivors of working age.